Start from a saved view, or filter by area, exchange and headquarters. Each row shows the pipeline, its most advanced asset and the next readout on record.
Lists by late-stage drug kind: biologics, small molecules, cell and gene therapies, RNA and oligonucleotide drugs, peptide drugs.
1457 of 1457 companies
| Company | Pipeline | Most advanced | Next readout | Market cap | Cash & inv. | Runway | R&D / yr |
|---|---|---|---|---|---|---|---|
EpkinPrivate | 1 asset: 1 Ph 1 | OKN4395Phase 1 · Non-Small Cell Lung Cancer | Jul 2028OKN4395 · Phase 1 | — | — | — | — |
ERIGENPrivate | 1 asset: 1 Ph 2 | KQ-2003Phase 1/2 · Multiple MyelomaWeak signal | 31 Dec 2027KQ-2003 · Phase 1 | — | — | — | — |
ERX PharmaceuticalsPrivate | 1 asset: 1 Ph 2 | ERX1000Phase 2 · ObesityWeak signal | May 2027ERX1000 · Phase 2 | — | — | — | — |
Esperion TherapeuticsPrivate | 2 assets: 2 approved | Approved assets only | None on record | — | $156MMar 2026 | ~6.2 qtrs | $44M |
Essen BiotechPrivate | 3 assets: 3 Ph 2 | CD123/CD33 CARTPhase 1/2 · Acute Myeloid Leukemia | 28 Dec 2027EB-SELECT Single-Target CAR-NK Cells · Phase 1/2 | — | — | — | — |
Essential PharmaPrivate | 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — |
Eurofarma LaboratoriosPrivate | 3 assets: 1 approved, 2 Ph 3 | EvogliptinPhase 3 · Type 2 DiabetesReliable signal | 31 Jan 2027Cenobamate · Phase 2 | — | — | — | — |
| 1 asset: 1 Ph 2 | CerebrolysinPhase 2 · Alzheimer's DiseasePartial signal | None on record | — | — | — | — | |
Evopoint Biosciences Inc.Private | 1 asset: 1 Ph 2 | ASP546CPhase 1/2 · Non-Small Cell Lung Cancer | 30 Dec 2026ASP546C · Phase 1/2 | — | — | — | — |
EwopharmaPrivate | 2 assets: 2 Ph 3 | SugemalimabPhase 3 · Non-Small Cell Lung CancerReliable signal | Dec 2029Sugemalimab · Phase 3 | — | — | — | — |
Exciva GmbHPrivate | 2 assets: 2 Ph 3 | DeramciclanePhase 2/3 · Alzheimer's Disease | Jan 2029Deramciclane · Phase 2/3 | — | — | — | — |
| 1 asset: 1 Ph 2 | YKST02Phase 2 · Multiple Myeloma | None on record | — | — | — | — | |
Ferrer InternacionalPrivate | 2 assets: 1 Ph 3, 1 Ph 2 | Loxapine (Adasuve)Phase 3 · SchizophreniaReliable signal | None on record | — | — | — | — |
Ferring PharmaceuticalsPrivate | 3 assets: 2 approved, 1 Ph 2 | olamkiceptPhase 2 · Ulcerative ColitisPartial signal | None on record | — | — | — | — |
| 1 asset: 1 Ph 1 | INN805Phase 1 · Non-Small Cell Lung Cancer | Dec 2026INN805 · Phase 1 | — | — | — | — | |
Flamingo TherapeuticsPrivate | 1 asset: 1 Ph 2 | DanvatirsenPhase 2 · Non-Small Cell Lung Cancer | None on record | — | — | — | — |
Fortis Therapeutics, Inc.Private | 1 asset: 1 Ph 1 | FOR46Phase 1 · Multiple MyelomaWeak signal | 31 Mar 2028FOR46 · Phase 2 | — | — | — | — |
FORUS Therapeutics Inc.Private | 1 asset: 1 approved | Approved assets only | Dec 2026Selinexor · Phase 2/3 | — | — | — | — |
Fosun Wanbang Pharma GroupPrivate | 1 asset: 1 Ph 3 | RoconkibartPhase 3 · PsoriasisReliable signal | None on record | — | — | — | — |
| 1 asset: 1 Ph 2 | FMC-376Phase 1/2 · Non-Small Cell Lung Cancer | Oct 2027FMC-376 · Phase 1/2 | — | — | — | — | |
| 1 asset: 1 Ph 2 | Gemcitabine (FF-10832)Phase 2 · Non-Small Cell Lung Cancer | May 2029Gemcitabine (FF-10832) · Phase 2 | — | — | — | — | |
FUJIFILM Toyama ChemicalPrivate | 1 asset: 1 Ph 3 | IguratimodPhase 3 · Rheumatoid ArthritisPartial signal | None on record | — | — | — | — |
Future Pak, LLCPrivate | 1 asset: 1 approved | Approved assets only | Dec 2026Crofelemer · Phase 2/3 | — | — | — | — |
G2GBio, Inc.Private | 1 asset: 1 Ph 1 | GB-5001Phase 1 · Alzheimer's DiseaseWeak signal | None on record | — | — | — | — |
G42 HealthcarePrivate | 1 asset: 1 Ph 3 | cadisegliatinPhase 3 · Type 1 DiabetesWeak signal | Apr 2027cadisegliatin · Phase 3 | — | — | — | — |
Gaelan MedicalPrivate | 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — |
Gebro Pharma GmbHPrivate | 1 asset: 1 Ph 3 | PiclidenosonPhase 3 · PsoriasisPartial signal | 31 Aug 2027Piclidenoson · Phase 2 | — | — | — | — |
GeneCradle IncPrivate | 1 asset: 1 Ph 1 | GC304Phase 1 · Severe Hypertriglyceridemia | Dec 2026GC304 · Phase 1 | — | — | — | — |
GeneCraft Inc.Private | 1 asset: 1 Ph 1 | RX001Phase 1 · Non-Small Cell Lung Cancer | None on record | — | — | — | — |
| 1 asset: 1 Ph 1 | GM101Phase 1 · Parkinson's Disease | 17 Feb 2027GM101 · Phase 1 | — | — | — | — | |
| 1 asset: 1 approved | Approved assets only | May 2027Lovotibeglogene autotemcel (Lyfgenia) · Phase 3 | — | — | — | — | |
Gensco Laboratories LLCPrivate | 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — |
GeropharmPrivate | 1 asset: 1 Ph 3 | EvogliptinPhase 3 · Type 2 DiabetesReliable signal | None on record | — | — | — | — |
GI Cell, Inc.Private | 1 asset: 1 Ph 2 | GIC-102Phase 1/2 · Multiple MyelomaWeak signal | None on record | — | — | — | — |
Gilgamesh PharmaPrivate | 1 asset: 1 Ph 2 | BlixeprodilPhase 2 · Major Depressive DisorderWeak signal | None on record | — | — | — | — |
GlaceumPrivate | 1 asset: 1 Ph 2 | VutiglabridinPhase 2 · Parkinson's DiseasePartial signal | None on record | — | — | — | — |
Gloria BiosciencesPrivate | 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — |
GluBio Therapeutics Inc.Private | 1 asset: 1 Ph 1 | GLB-001Phase 1 · Acute Myeloid Leukemia | None on record | — | — | — | — |
GNT Biotech & MedicalsPrivate | 1 asset: 1 Ph 3 | ChidamidePhase 3 · HR+/HER2- Metastatic Breast CancerReliable signal | 31 May 2028Chidamide · Phase 3 | — | — | — | — |
GPCR Therapeutics, Inc.Private | 1 asset: 1 Ph 2 | Burixafor (TG-0054)Phase 2 · Multiple MyelomaWeak signal | None on record | — | — | — | — |
| 2 assets: 1 Ph 3, 1 Ph 1 | TVAX-008Phase 3 · Chronic Hepatitis B | None on record | — | — | — | — | |
Grey Wolf TherapeuticsPrivate | 1 asset: 1 Ph 2 | GRWD5769Phase 1/2 · Non-Small Cell Lung Cancer | 30 Apr 2027GRWD5769 · Phase 1/2 | — | — | — | — |
Grit BiotechnologyPrivate | 1 asset: 1 Ph 1 | GT737Phase 1 · Acute Myeloid Leukemia | Jun 2030GT737 · Phase 1 | — | — | — | — |
Grünenthal GmbHPrivate | 4 assets: 3 approved, 1 Ph 3 | rexlemestrocel-LPhase 3 · Heart FailurePartial signal | Jul 2027rexlemestrocel-L · Phase 3 | — | — | — | — |
Guangdong Raynovent BiotechPrivate | 1 asset: 1 Ph 3 | RAY1225Phase 3 · Obesity | 1 Dec 2026RAY1225 · Phase 3 | — | — | — | — |
| 1 asset: 1 Ph 2 | BG1805Phase 1/2 · Acute Myeloid Leukemia | Mar 2027BG1805 · Phase 1/2 | — | — | — | — | |
| 1 asset: 1 Ph 1 | HNC364Phase 1 · Parkinson's DiseaseWeak signal | 31 Dec 2026HNC364 · Phase 1 | — | — | — | — | |
Guangzhou JOYO PharmaPrivate | 2 assets: 1 Ph 3, 1 Ph 2 | FudotinibPhase 3 · Non-Small Cell Lung Cancer | 31 Oct 2027Fudotinib · Phase 3 | — | — | — | — |
| 1 asset: 1 Ph 1 | MN-08Phase 1 | 30 Mar 2028MN-08 · Phase 1 | — | — | — | — | |
| 1 asset: 1 Ph 2 | XJN010Phase 2 · Parkinson's Disease | None on record | — | — | — | — | |
GV20 TherapeuticsPrivate | 1 asset: 1 Ph 2 | GV20-0251Phase 2 · Non-Small Cell Lung Cancer | 15 Dec 2026GV20-0251 · Phase 1/2 | — | — | — | — |
GW PharmaceuticalsPrivate | 1 asset: 1 approved | Approved assets only | 1 Aug 2027Cannabidiol (Epidiolex) · Approved | — | — | — | — |
Gyala TherapeuticsPrivate | 1 asset: 1 Ph 2 | CART84Phase 1/2 · Acute Myeloid Leukemia | 31 May 2029CART84 · Phase 1/2 | — | — | — | — |
Haihe BiopharmaPrivate | 1 asset: 1 Ph 3 | GlumetinibPhase 3 · Non-Small Cell Lung Cancer | None on record | — | — | — | — |
Halia TherapeuticsPrivate | 1 asset: 1 Ph 2 | HT-4253Phase 2 · Alzheimer's Disease | Feb 2028HT-4253 · Phase 2 | — | — | — | — |
Handa Neuroscience, LLCPrivate | 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — |
Hangzhou Dinovate BiotechPrivate | 1 asset: 1 Ph 2 | DNV001Phase 2 · Atherosclerotic Cardiovascular Disease | 30 Jun 2027DNV001 · Phase 2 | — | — | — | — |
| 4 assets: 1 Ph 3, 1 Ph 2, 1 Ph 1, 1 other | BHV-8000Phase 2/3 · Parkinson's Disease | 30 Jun 2027HL-300 · Phase 1/2 | — | — | — | — | |
| 1 asset: 1 Ph 1 | HPB-092Phase 1 · Acute Myeloid Leukemia | Jun 2027HPB-092 · Phase 1 | — | — | — | — | |
| 3 assets: 2 Ph 3, 1 Ph 2 | SanritatugPhase 3 · Multiple MyelomaWeak signal | 31 Mar 2027Sanritatug · Phase 2 | — | — | — | — | |
| 1 asset: 1 Ph 1 | WBC100Phase 1 · Acute Myeloid Leukemia | Dec 2026WBC100 · Phase 1 | — | — | — | — | |
HC Biopharma Inc.Private | 2 assets: 1 Ph 2, 1 Ph 1 | HC010Phase 2 · Non-Small Cell Lung Cancer | 30 Dec 2026HC010 · Phase 2 | — | — | — | — |
Hebei Senlang BiotechnologyPrivate | 2 assets: 1 Ph 2, 1 other | SENL103Phase 1/2 · Multiple MyelomaWeak signal | 1 Feb 2028SENL103 · Phase 1/2 | — | — | — | — |
| 1 asset: 1 Ph 1 | TGI-5Phase 1 · Non-Small Cell Lung Cancer | 31 Oct 2027TGI-5 · Phase 1 | — | — | — | — | |
HekaBio K.K.Private | 1 asset: 1 Ph 2 | TroculeucelPhase 1/2 · Alzheimer's DiseaseWeak signal | Mar 2028Troculeucel · Phase 1/2 | — | — | — | — |
HELP TherapeuticsPrivate | 1 asset: 1 Ph 3 | HiCM-188 (allogeneic iPSC-cardiomyocytes)Phase 3 · Heart FailurePartial signal | 30 Jun 2027HiCM-188 (allogeneic iPSC-cardiomyocytes) · Phase 3 | — | — | — | — |
Henan Genuine BiotechPrivate | 4 assets: 1 Ph 3, 3 Ph 2 | AzvudinePhase 3 · HIVPartial signal | Dec 2026CL-197 · Phase 2 | — | — | — | — |
HiFiBiO TherapeuticsPrivate | 2 assets: 2 Ph 1 | EmunkitugPhase 1 · Non-Small Cell Lung Cancer | Dec 2026Emunkitug · Phase 1 | — | — | — | — |
| 1 asset: 1 Ph 2 | HBI-002Phase 2 · Parkinson's Disease | 31 Dec 2026HBI-002 · Phase 2 | — | — | — | — | |
HMNC Brain HealthPrivate | 1 asset: 1 Ph 2 | NelivaptanPhase 2 · Major Depressive DisorderPartial signal | None on record | — | — | — | — |
| 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — | |
| 1 asset: 1 Ph 2 | Carbidopa/levodopa (WD-1603)Phase 2 · Parkinson's DiseasePartial signal | None on record | — | — | — | — | |
| 4 assets: 2 Ph 2, 2 Ph 1 | Hrain anti-BCMA CAR-TPhase 2 · Multiple MyelomaWeak signal | None on record | — | — | — | — | |
Huabo Biopharm Co.Private | 2 assets: 2 Ph 3 | HB0017Phase 3 · PsoriasisPartial signal | 31 Dec 2026HB0017 · Phase 1 | — | — | — | — |
Huahui HealthPrivate | 2 assets: 1 Ph 3, 1 Ph 1 | Libevitug (HH-003)Phase 3 · Chronic Hepatitis Delta | Aug 2027HH160 · Phase 1 | — | — | — | — |
Humanetics CorporationPrivate | 1 asset: 1 Ph 2 | BIO 300Phase 2 · Non-Small Cell Lung CancerWeak signal | None on record | — | — | — | — |
Hummingbird BiosciencePrivate | 2 assets: 2 Ph 2 | NezutatugPhase 1/2 · Non-Small Cell Lung CancerWeak signal | Jul 2027ENV-501 · Phase 1/2 | — | — | — | — |
HuniLife Biotechnology, Inc.Private | 1 asset: 1 Ph 2 | HuL001Phase 1/2 · Multiple Myeloma | 30 Nov 2027HuL001 · Phase 1/2 | — | — | — | — |
HUYABIO International, LLC.Private | 5 assets: 2 Ph 3, 1 Ph 2, 2 Ph 1 | ChidamidePhase 3 · HR+/HER2- Metastatic Breast CancerReliable signal | 30 Dec 2026GH21 · Phase 2 | — | — | — | — |
Iambic Therapeutics, IncPrivate | 1 asset: 1 Ph 2 | IAM1363Phase 1/2 · Non-Small Cell Lung Cancer | Oct 2028IAM1363 · Phase 1/2 | — | — | — | — |
IASO BiotherapeuticsPrivate | 2 assets: 1 Ph 3, 1 Ph 1 | Equecabtagene autoleucelPhase 3 · Multiple Myeloma | None on record | — | — | — | — |
iCamuno Biotherapeutics Ltd.Private | 2 assets: 2 Ph 1 | ALC01Phase 1 · Parkinson's Disease | 15 Dec 2027ALC01 · Phase 1 | — | — | — | — |
iCell Gene TherapeuticsPrivate | 4 assets: 1 Ph 2, 3 Ph 1 | ICG318Phase 2 · Systemic Lupus Erythematosus | 31 Dec 2027ICG318 · Phase 1 | — | — | — | — |
Ichnos SciencesPrivate | 1 asset: 1 Ph 2 | ABBV-2001Phase 1/2 · Multiple Myeloma | Jul 2027ABBV-2001 · Phase 1 | — | — | — | — |
IdB HoldingPrivate | 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — |
| 1 asset: 1 Ph 2 | IDP-121Phase 1/2 · Multiple Myeloma | 30 Jul 2028IDP-121 · Phase 1/2 | — | — | — | — | |
iLeukon Therapeutics, Inc.Private | 1 asset: 1 Ph 2 | ILKN421HPhase 2 · Non-Small Cell Lung Cancer | Jun 2029ILKN421H · Phase 2 | — | — | — | — |
| 1 asset: 1 Ph 1 | IBR733Phase 1 · Acute Myeloid Leukemia | 1 Jul 2027IBR733 · Phase 1 | — | — | — | — | |
Imbria PharmaceuticalsPrivate | 1 asset: 1 Ph 2 | NinerafaxstatPhase 2 · Heart FailureWeak signal | Dec 2026Ninerafaxstat · Phase 2 | — | — | — | — |
Immedica Pharma ABPrivate | 1 asset: 1 approved | Approved assets only | Dec 2029Ganaxolone · Phase 3 | — | — | — | — |
Immune-Onc TherapeuticsPrivate | 1 asset: 1 Ph 1 | IO-202Phase 1 · Acute Myeloid LeukemiaWeak signal | None on record | — | — | — | — |
Immunitas TherapeuticsPrivate | 1 asset: 1 Ph 2 | RezorstobartPhase 1/2 · Non-Small Cell Lung CancerWeak signal | None on record | — | — | — | — |
Immuno Cure BioTechPrivate | 1 asset: 1 Ph 1 | AV000103A (ICVAX)Phase 1 · HIVWeak signal | None on record | — | — | — | — |
Immunobrain CheckpointPrivate | 1 asset: 1 Ph 1 | IBC-Ab002Phase 1 · Alzheimer's DiseasePartial signal | None on record | — | — | — | — |
| 1 asset: 1 Ph 1 | KB-GDT-01Phase 1 · Non-Small Cell Lung Cancer | None on record | — | — | — | — | |
Immunophotonics, Inc.Private | 1 asset: 1 Ph 3 | N-dihydrogalactochitosanPhase 2/3 · Colorectal Cancer | Dec 2033N-dihydrogalactochitosan · Phase 2/3 | — | — | — | — |
ImmunworkPrivate | 1 asset: 1 Ph 2 | TE-8105Phase 2 · ObesityWeak signal | Feb 2028TE-8105 · Phase 2 | — | — | — | — |
ImmVira PharmaPrivate | 1 asset: 1 Ph 2 | T3011Phase 1/2 · Non-Small Cell Lung CancerWeak signal | 31 Dec 2028T3011 · Phase 2 | — | — | — | — |
Imperial College LondonPrivate | 1 asset: 1 Ph 2 | RAD101Phase 2 · Brain Metastases | None on record | — | — | — | — |
Incendia TherapeuticsPrivate | 1 asset: 1 Ph 1 | EnsavatatugPhase 1 · Non-Small Cell Lung Cancer | None on record | — | — | — | — |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov). Cash shows its balance-sheet month; runway shows a month only when it comes from an earlier report.